Arcturus Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results and Provide Corporate Update on March 28, 2023

Arcturus to present at the Guggenheim Healthcare Talks: Genomic Medicines & Rare Disease Day, April 3, 2023

SAN DIEGO--(BUSINESS WIRE)-- Arcturus Therapeutics Holdings Inc. (the “Company,” “Arcturus,” Nasdaq: ARCT), a global late-stage clinical messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases, today announced that it will release its financial results for the quarter and year ended December 31, 2022 after the market close on Tuesday, March 28 and will also host a conference call and webcast at 4:30 p.m. Eastern Time on March 28, 2023.

The Company also announced it will present at the Guggenheim Healthcare Talks: Genomic Medicines & Rare Disease Day on April 3, 2023, at 2:10 p.m. ET.

Arcturus Therapeutics Fourth Quarter and Full Year 2022 Earnings Conference Call

• Tuesday, March 28, 2023 @ 4:30 p.m. ET
• Domestic: 1-877-407-0784
• International: 1-201-689-8560
• Conference ID: 13735876
• Webcast: Link

Guggenheim Healthcare Talks: Genomic Medicines & Rare Disease Day (Fireside Chat)

• Monday, April 3, 2023 (2:10 p.m. ET)

A webcast and replay of the presentation will be available on the “Investor Relations/Events” section of the Company’s website at: https://ir.arcturusrx.com/investor-calendar

About Arcturus Therapeutics
Founded in 2013 and based in San Diego, California, Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT) is a global late-stage clinical mRNA medicines and vaccines company with enabling technologies: (i) LUNAR® lipid-mediated delivery, (ii) STARR™ mRNA Technology (samRNA) and (iii) mRNA drug substance along with drug product manufacturing expertise. Arcturus’ diverse pipeline of RNA therapeutic and vaccine candidates includes mRNA vaccine programs for SARS-CoV-2 (COVID-19) and Influenza, and other programs to potentially treat ornithine transcarbamylase (OTC) deficiency, and cystic fibrosis, along with partnered programs including glycogen storage disease type III. Arcturus’ versatile RNA therapeutics platforms can be applied toward multiple types of nucleic acid medicines including messenger RNA, small interfering RNA, circular RNA, antisense RNA, self-amplifying RNA, DNA, and gene editing therapeutics. Arcturus’ technologies are covered by its extensive patent portfolio (patents and patent applications issued in the U.S., Europe, Japan, China, and other countries). For more information, visit www.ArcturusRx.com. In addition, please connect with us on Twitter and LinkedIn.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230307005396/en/

IR and Media Contacts

Arcturus Therapeutics

Neda Safarzadeh

VP, Head of IR/PR/Marketing

IR@arcturusrx.com



Kendall Investor Relations

Carlo Tanzi, Ph.D.

(617) 914-0008

ctanzi@kendallir.com

Source: Arcturus Therapeutics Holdings Inc.